# Tempest Therapeutics, Inc.: Form 10-K for the period ended Dec 31, 2015

- Company: [Tempest Therapeutics, Inc.](/companies/tpst.md) (CIK 1544227)
- Form: 10-K
- Filed: 2016-02-26
- Accepted by EDGAR: Feb 26, 2016, 17:33 ET
- Period: 2015-12-31
- Accession: 0001544227-16-000008
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1544227/000154422716000008/ovas-20151231x10k.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1544227/000154422716000008/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 12 months, 2015-01-01 to 2015-12-31 | $277.0k | us-gaap:Revenues |
| Cost of revenue | 12 months, 2015-01-01 to 2015-12-31 | $2.2m | us-gaap:CostOfRevenue |
| Research and development | 12 months, 2015-01-01 to 2015-12-31 | $18.4m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months, 2015-01-01 to 2015-12-31 | $51.6m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months, 2015-01-01 to 2015-12-31 | −$72.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 12 months, 2015-01-01 to 2015-12-31 | $75.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 12 months, 2015-01-01 to 2015-12-31 | −$73.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 12 months, 2015-01-01 to 2015-12-31 | −$2.70 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 12 months, 2015-01-01 to 2015-12-31 | −$50.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months, 2015-01-01 to 2015-12-31 | $5.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-12-31 | $43.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-12-31 | $129.9m | us-gaap:AssetsCurrent |
| Total assets | at 2015-12-31 | $138.6m | us-gaap:Assets |
| Current liabilities | at 2015-12-31 | $11.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-12-31 | $11.8m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-12-31 | $126.8m | us-gaap:StockholdersEquity |

## Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/1544227/000154422716000008/ovas-20151231x10k.htm

Filed Feb 26, 2016.
Source: SEC EDGAR, the filing index for accession 0001544227-16-000008. Last ingested by Listed: Nov 15, 2026, 00:20 ET. No prices; not investment advice.
